Prostate cancer--not a benign malignancy.
Explore the source record for details and available documents.
Aged↗
Biomedical subjects
E Totonchi
Publications and source records attributed to E Totonchi.
Suppression of cytophilic antibody ('arming' factor) in the sera of patients with prostatic cancer by human seminal plasma.
The 'arming' of normal peripheral blood leukocytes (PBL) by cytophilic antibody in the sera of prostatic cancer patients is suppressed by pretreatment of PBL with normal human seminal plasma (HuSPl). Suppression of cytophilic antibody by HuSPl extends the spectrum of immunologic reactions on which SPl has an immunosuppressive effect and may provide further insight into the possible role of SPl in the natural history of prostatic cancer.
Adult↗
Adjuvant immunotherapy with bacillus Calmette-Guérin in prostatic cancer.
Ninety-two patients with histologically proved prostatic cancer were studied. Forty-six patients were treated with bacillus Calmette-Guérin (BCG) adjuvant immunotherapy, and 46 other patients, matched for stage and hormone therapy, served as controls. Survival from the time of histologic diagnosis was sixteen and one-half months longer (thirty-seven and one-half versus twenty-one months) in the BCG-treated patients. There was no mortality and only minimal morbidity. Changes in some immunologic parameters (white blood cell count, skin tests) suggest an immune response.
Aged↗
Effect of diethylstilboesterol diphosphate on tumour-assoiciated immunity in prostatic cancer. A preliminary report.
Explore the source record for details and available documents.
Adenocarcinoma↗